Clinical trial for patients with newly diagnosed Ewing's sarcoma with isolated lung metastases.
14730
European Ewing Tumor Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G. 99), AEWS0331
Pediatrics
Dunsmore Kimberly, P
UVa Health System, Department of Pediatrics seeks: children, adolescents, women and men with a type of cancer called Ewings sarcoma that has spread to the lung or pleura for research study. The patient must be less than 50 years old at the time of study enrollment. Patients with Ewings sarcoma are commonly treated with chemotherapy, surgery and/or radiation therapy. This study is being done: (a) to compare survival of standard treatment and whole lung irradiation versus an experimental therapy with intensive high dose drug therapy followed by stem cell transplant; (b) to see if there is genetic information in the tumor cells that may help researchers predict how a subject will respond to therapy; and (c) to see if there are any microscopic tumor cells left in the bone marrow after treatment and to find out if this has any effect on the outcome of the treatment. The study involves taking FDA approved chemotherapy agents, as well as the following tests which are all standard of care: blood draws, physical exams, urinalyses, tumor biopsy (in certain situations), bone marrow aspirates, heart tests (EKG and Echocardiogram), CT/MRI and bone scans. The patient may also receive radiation therapy, surgery or stem cell transplant. If you receive the standard therapy, you will have no extra visits compared to non-study treatment. If you receive the experimental therapy, your treatment will be 3-5 months shorter than non-study treatment because you will receive intensive high dose chemotherapy for 7 days followed by stem cell transplant on Day 8 rather than 7 cycles of standard chemotherapy. As such, the experimental therapy will also have fewer clinic visits. All subjects will be asked to visit the doctors office for follow-up exams for at least 5 years after treatment is completed. You and/or your insurance will be billed for all study related medication, tests, treatment, and procedures. No compensation is provided for this study. Contact Information: For more information please contact: " Candace Hudspeth, CCRC " Tel: 434-982-1091 Email: ckh3k@virginia.edu " IRB-HSR # 14730 (COG AEWS0331) Principal Investigator: Kimberly P. Dunsmore, MD
Hematology/Oncology
Adult
Child
Pediatric Cancers: Bone Cancer
Pediatrics
Cancer (Oncology)
Ill
Candy Hudspeth
ckh3k@virginia.edu
4349821091
